# Literature References

This document lists all peer-reviewed literature and clinical trials that inform the mathematical models and parameters used in the drug resistance simulation. 
---

## References
1. Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol. 2006;3(8):406-7. doi: 10.1038/ncponc0560. PMID: 16894366.

2. Dhawan A, Nichol D, Kinose F, Abazeed ME, Marusyk A, Haura EB, et al. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer. Sci Rep. 2017;7(1):1232. doi: 10.1038/s41598-017-00791-8. PMID: 28450729. PMCID: PMC5430816.

3. Shah S, McRae AF, Marioni RE, Harris SE, Gibson J, Henders AK, et al. Genetic and environmental exposures constrain epigenetic drift over the human life course. Genome Res. 2014;24(11):1725-33. doi: 10.1101/gr.176933.114. PMID: 25249537. PMCID: PMC4216914.

4. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-9. doi: 10.1200/JCO.2007.13.9030. PMID: 18506026.

5. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41-50. doi: 10.1056/NEJMoa1913662. PMID: 31751012.

6. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. PMID: 32955177.

7. Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. PMID: 28899864. PMCID: PMC5895851.

8. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-90. doi: 10.1038/nm.1789. PMID: 18670422. PMCID: PMC2820391.

9. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.3007094. PMID: 24553385. PMCID: PMC4017867.

10. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. doi: 10.1126/scitranslmed.3002003. PMID: 21430269. PMCID: PMC3132801.

11. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17(6):1616-22. doi: 10.1158/1078-0432.CCR-10-2692. PMID: 21135146. PMCID: PMC3060283.

12. Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262-9. doi: 10.1038/nm.4040. PMID: 26828195. PMCID: PMC4900892.

13. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, et al. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov. 2015;5(7):713-22. doi: 10.1158/2159-8290.CD-15-0399. PMID: 25934077. PMCID: PMC4497836.

14. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-43. doi: 10.1126/science.1141478. PMID: 17463250.

15. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69-80. doi: 10.1016/j.cell.2010.02.027. PMID: 20371346. PMCID: PMC2851638.

16. Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, et al. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 2018;84(6):1156-1169. doi: 10.1111/bcp.13534. PMID: 29381826. PMCID: PMC5980546.

17. Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 2014;57(20):8249-67. doi: 10.1021/jm500973a. PMID: 25271963.

18. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-56. doi: 10.1200/JCO.1989.7.11.1748. PMID: 2681557.

19. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010;10(2):147-56. doi: 10.1038/nrc2789. PMID: 20075923.

20. Gunnarsson EB, Magnússon BV, Foo J. Optimal dosing of anti-cancer treatment under drug-induced plasticity. NPJ Syst Biol Appl. 2025;11(1):98. doi: 10.1038/s41540-025-00571-5. PMID: 40850942. PMCID: PMC12375710.

---
*Last updated: December 2025*

